GPS Rebrands as “Thredd” to Reflect Its Unique Position as the Go to Payments Partner of Innovators Worldwide
27.4.2023 12:00:00 EEST | Business Wire | Press release
Global Processing Services, a next generation global payments platform behind the leading fintechs, digital banks, and embedded finance providers across the UK, Europe, Asia, Middle East and North America, has today rebranded as “Thredd,” to reflect the company’s pivotal role in weaving together the different ‘threads’ of the global payments ecosystem to fuel the growth of electronic payments.
With a new leadership team comprising of industry veterans coupled with the backing of future-focused investors, this rebranding signals the next phase of customer partnership and product innovation to bring the aspirations of innovative payments visionaries to life.
Thredd is known for its customer-centred approach to enable payments innovators to launch new card programmes quickly, easily, and cost effectively. Thredd has created a unique niche as a hands-on, modern processor providing reliable digital payment processing capabilities, including real-time, bespoke card management tools, reporting, and world-class fraud prevention technology.
Certified by both Visa and Mastercard, and supporting debit, prepaid and credit programs, Thredd has enabled modern payments issuer processing since 2007 and has earned a reputation as a trusted, reliable and scalable platform.
Today, Thredd’s next-gen platform processes billions of transactions annually and powers over 100 customers across 44 countries and a broad range of use cases. Thredd is the processing partner of choice for an array of verticals, including digital banking, Buy Now Pay Later (BNPL), Travel, and Banking-as-a-Service (BaaS).
One of Thredd’s fastest growing customers today is “financial super app” Curve which allows customers to combine most debit, credit, and loyalty cards into one platform and a linked smart card for payments. Thredd has provided the issuer processing firepower for Curve’s platform since it was founded in 2016, supporting the innovative fintech as it has scaled to over 4 million customers, diversified its products, and expanded into international markets.
“Our rebranding to Thredd marks a new era for our company as we begin the next phase of our growth. We’ve spent the last six months building our management team with industry veterans to expand our platform capabilities and deepen our commitment to serving the needs of the most innovative fintechs and banks in the world, said Kevin Schultz, Chief Executive Officer of Thredd.
“Our new brand reflects our renewed focus on enabling our clients to create a more interconnected, accessible, and seamless payments ecosystem. With our experienced team and owners, we’re confident in our vision to bring our partnership approach to modern payments processing to innovators worldwide.”
Explaining why the name Thredd was chosen, Betsy Samuel, Chief Marketing Officer of Thredd, said: “Our clients, partners and team members have told us that we are the ultimate connector, bringing true partnership to the world of payments. This is our DNA, and we wanted a new name to reflect this special identity as well as our expanding position as a pivotal modern payments processor at the heart of the constantly evolving digital economy. We are proud to relaunch with a name which reflects our unique role and reputation as a critical ‘thread’ of the fabric in the ecosystem.”
Thredd is backed by an experienced private equity consortium with specialist experience in scaling payments-related tech businesses, including Advent International, Viking Global Investors, Temasek, and MissionOG; with institutional investors including Mastercard and Visa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005429/en/
Contact information
Media:
Louisa Bartoszek
Head of Communications
louisa.bartoszek@thredd.com
Cognito Media
thredd@cognitomedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
